查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1476369

2030 年吸入藥物市場預測：按藥物類別、分銷管道、應用和區域分類的全球分析

Inhalable Drugs Market Forecasts to 2030 - Global Analysis By Drug Class, Distribution Channel, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球吸入藥物市場規模為 343 億美元，預計到 2030 年將達到 619 億美元，預測期內複合年成長率為 8.8%。

吸入藥物市場包括透過吸入途徑輸送的針對呼吸道和全身疾病的藥物。吸入劑直接進入呼吸系統，可以快速吸收到血液中並局部治療效果。吸入藥物市場在現代醫學中發揮重要作用，為各種呼吸系統疾病和全身性疾病的治療提供創新的解決方案。吸入藥物經由吸入器或霧化器給藥，可快速、有針對性地直接輸送至呼吸系統，確保有效吸收和起效。

根據美國疾病管制與預防中心（CDC）預測，2021年美國將有超過2,500萬人患有氣喘，約佔成人的8.0%和兒童的6.5%。世界衛生組織（WHO）2022年10月發表的論文顯示，全球整體，從2015年的12%增至2050年的22%，備受關注。

呼吸道疾病增加

氣喘、慢性阻塞性肺病（COPD）和囊腫纖維化等呼吸系統疾病的盛行率不斷上升，推動了吸入器市場的顯著成長。隨著這些疾病在世界各地變得越來越普遍，對有效治療方案的需求不斷成長。與傳統口服藥物相比，吸入藥物具有多種優勢，包括直接靶向輸送至肺部、起效快以及較少的全身副作用。此外，吸入技術的進步促進了創新輸送設備的發展，提高了患者的便利性和對治療方法的依從性。

濫用吸入器的風險

吸入劑可能會被故意濫用於休閒目的，或因給藥技術不當而無意中濫用。存在濫用的可能性，尤其是精神活性藥物。這種濫用不僅會損害治療效果，還會引起對病人安全和監管合規性的擔憂。因此，醫療保健提供者和監管機構強調嚴格的監控和教育，以降低濫用風險，這可能會限制市場擴張。

生技藥品吸入給藥的可能性

吸入式生技藥品製劑的出現透過提供更有效、對患者友善的給藥方法，顯著增強了吸入式藥物市場。生技藥品是源自生物體的大分子，徹底改變了氣喘、慢性阻塞性肺病(COPD) 和囊腫纖維化等各種慢性疾病的治療模式。吸入生物製藥的可能性提供了一種非侵入性、無針頭的選擇，使它們能夠直接施用到肺部，而許多呼吸道疾病都發生在肺部。這不僅提高了患者的舒適度和依從性，而且有可能透過有針對性的給藥和減少全身副作用來改善治療結果。

開發成本高

高開發成本是吸入器市場的主要障礙，抑制了創新和新產品的推出。吸入藥物的複雜開發過程涉及廣泛的研究、臨床試驗和監管核准，所有這些都需要高昂的成本。製藥公司經常面臨平衡這些高成本與潛在市場需求和盈利的挑戰。然而，吸入給藥系統的複雜性需要先進的技術和專業知識，進一步加劇了不斷飆升的開發成本。

COVID-19 的影響：

隨著病毒向呼吸系統的傳播，呼吸藥物輸送系統受到關注，對吸入藥物的需求增加。對呼吸困難等 COVID-19 症狀的有效治療方法的需求導致了吸入藥物的研發激增。封鎖和社會疏離措施擾亂了供應鏈和分銷網路，導致生產和分銷暫時受挫。醫療保健系統優先考慮了 COVID-19 的管理，轉移了人們對其他醫療疾病（包括通常使用吸入藥物治療的呼吸道疾病）的注意力和資源。

預計白三烯改質劑部分在預測期內將是最大的

預計白三烯改質劑部分在預測期內將是最大的。透過針對白三烯介導的發炎途徑，這些藥物提供了一種治療呼吸系統疾病的新方法，特別是影響全世界數百萬人的氣喘。與傳統的支氣管擴張劑不同，白三烯調節劑透過抑制白三烯的產生或作用來發揮作用，從而抑制氣道發炎和收縮。這種機制不僅可以緩解症狀，還有助於預防氣喘惡化並改善整體肺功能。

預計零售藥局領域在預測期內複合年成長率最高

零售藥房領域預計在預測期內複合年成長率最高。這是因為這些藥房是可到達的分銷中心，使消費者可以輕鬆獲得吸入藥物。隨著氣喘和慢性阻塞性肺病等呼吸系統疾病的盛行率不斷增加，在附近藥局購買吸入器非常方便，可以顯著提高患者對治療方法的依從性。此外，零售藥局經常提供病患教育和諮詢服務，以協助正確的吸入技術和藥物管理。此外，零售藥局作為技術創新中心，儲備新的吸入製劑和藥物傳輸設備，透過響應不斷變化的患者需求和偏好來推動市場成長。

佔比最大的地區：

預計亞太地區在預測期內將佔據最大的市場佔有率。該地區國家正在增加對醫療基礎設施和服務的投資，並更加關注創新的藥物輸送系統，包括吸入藥物。中等收入人口的成長和生活方式的改變導致呼吸系統疾病的增加，進一步推動了該地區對吸入器的需求。亞太地區的醫療保健支出持續飆升，製藥公司擴大投資於吸入藥物製劑的研發，推動了該地區吸入藥物市場的成長。

複合年成長率最高的地區：

預計亞太地區在預測期內將呈現良好的成長動能。亞太地區的政府法規透過營造有利於創新、安全和可近性的環境，在加強吸入器市場方面發揮關鍵作用。藥品註冊核准流程和製造標準等法律規範確保吸入藥物在進入市場之前符合嚴格的品質和功效標準。因此，政府法規不僅保護了公眾健康，也促進了亞太地區吸入器市場的成長。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球吸入藥物市場：依藥物類別

  • 長效BETA拮抗劑（LABA）
  • 吸入性皮質類固醇
  • 長效毒蕈鹼拮抗劑（LAMA）
  • 白三烯調節劑
  • 其他藥物類別

第6章全球吸入藥物市場：依分銷管道分類

  • 網路藥房
  • 零售藥房
  • 醫院藥房
  • 其他分銷管道

第7章全球吸入藥物市場：依應用分類

  • 非呼吸系統疾病
  • 呼吸系統疾病
  • 其他用途

第8章全球吸入器市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第 10 章 公司概況

  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Cipla Inc
  • GlaxoSmithKline plc
  • Merck & Co., Inc
  • Mundipharma International
  • Novartis International AG
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd
  • Vectura Group Ltd
  • Viatris Inc
Product Code: SMRC25915

According to Stratistics MRC, the Global Inhalable Drugs Market is accounted for $34.3 billion in 2023 and is expected to reach $61.9 billion by 2030 growing at a CAGR of 8.8% during the forecast period. The inhalable drugs market encompasses pharmaceutical products delivered through inhalation routes, targeting respiratory conditions or systemic diseases. Inhalable drugs are administered directly to the respiratory system, allowing for rapid absorption into the bloodstream and localized therapeutic effects. The inhalable drugs market serves as a vital avenue in modern medicine, offering innovative solutions for the treatment of various respiratory diseases and systemic conditions. Inhalable drugs, administered through inhalers or nebulizers, provide rapid and targeted delivery directly to the respiratory system, ensuring efficient absorption and onset of action.

According to the Centers for Disease Control and Prevention (CDC), more than 25 million people had asthma in the U.S. in 2021, accounting for approximately 8.0% of adults and 6.5% of children. According to an article released by the World Health Organization in October 2022, globally, the percentage of individuals aged 60 years and above is likely to increase twofold from 12% in 2015 to 22% by 2050.

Market Dynamics:

Driver:

Rising prevalence of respiratory diseases

The increasing prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis has spurred significant growth in the inhalable drugs market. As these conditions become more prevalent globally, the demand for effective treatment options has escalated. Inhalable drugs offer several advantages over traditional oral medications, including targeted delivery directly to the lungs, rapid onset of action, and reduced systemic side effects. Additionally, advancements in inhalation technology have led to the development of innovative delivery devices, improving patient convenience and adherence to treatment regimens.

Restraint:

Risk of misusing inhalable medications

Inhalers can be misused intentionally for recreational purposes or unintentionally due to improper administration techniques. There's a potential for abuse, particularly with medications that have psychoactive effects. Such misuse not only compromises the effectiveness of the treatment but also raises concerns regarding patient safety and regulatory compliance. Consequently, healthcare providers and regulatory agencies emphasize stringent monitoring and education to mitigate the risk of misuse, which can potentially limit the market's expansion.

Opportunity:

Possibility of inhaling biologics delivery

The emergence of inhalable biologics delivery has significantly bolstered the Inhalable Drugs Market by offering a more efficient and patient-friendly administration method. Biologics, which are large molecules derived from living organisms, have revolutionized the treatment landscape for various chronic conditions such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. The possibility of inhaling biologics presents a non-invasive, needle-free alternative, allowing for direct delivery to the lungs where many respiratory diseases originate. This not only enhances patient comfort and adherence but also potentially improves therapeutic outcomes through targeted delivery and reduced systemic side effects.

Threat:

High development costs

High development costs act as a significant barrier in the inhalable drugs market, impeding innovation and the introduction of new products. The intricate process of developing inhalable drugs involves extensive research, clinical trials, and regulatory approvals, all of which incur substantial expenses. Pharmaceutical companies often face the challenge of balancing these high costs with potential market demand and profitability. However, the complexity of inhalable drug delivery systems necessitates sophisticated technologies and expertise, further contributing to elevated development expenses.

Covid-19 Impact:

With the respiratory nature of the virus, there was an increased focus on respiratory drug delivery systems, driving demand for inhalable drugs. The need for effective treatments for Covid-19 symptoms, such as respiratory distress, led to a surge in research and development of inhalable medications. Lockdowns and social distancing measures disrupted the supply chain and distribution networks, causing temporary setbacks in production and distribution. Healthcare systems prioritized Covid-19 management, diverting attention and resources away from other medical conditions, including respiratory diseases typically treated with inhalable drugs.

The leukotriene modifiers segment is expected to be the largest during the forecast period

Leukotriene Modifiers segment is expected to be the largest during the forecast period. By targeting the inflammatory pathway mediated by leukotrienes, these medications offer a novel approach to managing respiratory conditions, particularly asthma, which affects millions worldwide. Unlike traditional bronchodilators, leukotriene modifiers work by inhibiting the production or action of leukotrienes, thereby reducing airway inflammation and constriction. This mechanism not only provides symptom relief but also helps in preventing asthma exacerbations and improving overall lung function.

The retail pharmacies segment is expected to have the highest CAGR during the forecast period

Retail Pharmacies segment is expected to have the highest CAGR during the forecast period as these pharmacies serve as accessible points of distribution, making inhalable drugs readily available to consumers. With the increasing prevalence of respiratory ailments like asthma and COPD, the convenience of obtaining inhalable medications from nearby pharmacies significantly improves patient adherence to treatment regimens. Moreover, retail pharmacies often offer patient education and counseling services, aiding in proper inhaler technique and medication management. Furthermore, retail pharmacies serve as hubs for innovation, stocking new inhalable drug formulations and delivery devices, thus driving market growth by catering to evolving patient needs and preferences.

Region with largest share:

Asia Pacific region is expected to hold the largest share of the market over the projected period. As countries in the region invest more in healthcare infrastructure and services, there is an increased focus on innovative drug delivery systems, including inhalable drugs. The growing middle-class population and changing lifestyles contribute to the rise in respiratory disorders, further driving the demand for inhalable drugs in the region. With healthcare spending continuing to surge in Asia Pacific, pharmaceutical companies are increasingly investing in research and development of inhalable drug formulations, thus propelling the growth of the inhalable drugs market in the region.

Region with highest CAGR:

Asia Pacific region is estimated to witness profitable growth during the extrapolated period. Government regulations in the Asia Pacific region have played a substantial role in enhancing the Inhalable Drugs Market by fostering a favorable environment for innovation, safety, and accessibility. Regulatory frameworks, such as the approval processes for drug registration and manufacturing standards, ensure that inhalable drugs meet stringent quality and efficacy standards before entering the market. As a result, government regulations have not only safeguarded public health but also catalyzed the growth of the inhalable drugs market in the Asia Pacific region.

Key players in the market

Some of the key players in Inhalable Drugs market include AstraZeneca, Boehringer Ingelheim International GmbH, Cipla Inc, GlaxoSmithKline plc, Merck & Co., Inc, Mundipharma International, Novartis International AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Vectura Group Ltd and Viatris Inc.

Key Developments:

In November 2023, Sanofi, a pharmaceutical company, announced that Dupixent significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating U.S. Food and Drug Administration submission and confirming potential to become first approved biologic for this serious disease

In July 2023, Viatris Inc., a global healthcare company, and Kindeva Drug Delivery L.P., a pharmaceutical contract development and manufacturing organization, launched Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol, the first generic version of AstraZeneca's Symbicort with an abbreviated new drug application (ANDA) approved by the U.S. Food and Drug Administration (FDA).

In January 2023, AstraZeneca received approval from the U.S. Food and Drug Administration for Airsupra (albuterol and budesonide) inhalation aerosol. Airsupra aims to reduce the risk of asthma exacerbations in individuals aged 18 years and older.

In November 2022, PT027 had been recommended by the U.S.FDA Advisory Committee as new rescue treatment for asthma. T027 is a potential first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication in the U.S. containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS). It is being developed by AstraZeneca, a pharmaceutical company and Avillion, a global drug development company.

In March 2022, Viatris Inc. and Kindeva Drug Delivery L.P. received FDA approval for Breyna, a drug-device combination therapy recommended for patients with asthma or chronic obstructive pulmonary disease (COPD).

Drug Classes Covered:

  • Long-acting Beta Antagonists (LABAs)
  • Inhaled Corticosteroids
  • Long-acting Muscarinic Antagonists (LAMAs)
  • Leukotriene Modifiers
  • Other Drug Classes

Distribution Channels Covered:

  • Online Pharmacies
  • Retail Pharmacies
  • Hospital Pharmacies
  • Other Distribution Channels

Applications Covered:

  • Non-respiratory Diseases
  • Respiratory Diseases
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Inhalable Drugs Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Long-acting Beta Antagonists (LABAs)
  • 5.3 Inhaled Corticosteroids
  • 5.4 Long-acting Muscarinic Antagonists (LAMAs)
  • 5.5 Leukotriene Modifiers
  • 5.6 Other Drug Classes

6 Global Inhalable Drugs Market, By Distribution Channel

  • 6.1 Introduction
  • 6.2 Online Pharmacies
  • 6.3 Retail Pharmacies
  • 6.4 Hospital Pharmacies
  • 6.5 Other Distribution Channels

7 Global Inhalable Drugs Market, By Application

  • 7.1 Introduction
  • 7.2 Non-respiratory Diseases
  • 7.3 Respiratory Diseases
  • 7.4 Other Applications

8 Global Inhalable Drugs Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 AstraZeneca
  • 10.2 Boehringer Ingelheim International GmbH
  • 10.3 Cipla Inc
  • 10.4 GlaxoSmithKline plc
  • 10.5 Merck & Co., Inc
  • 10.6 Mundipharma International
  • 10.7 Novartis International AG
  • 10.8 Pfizer Inc
  • 10.9 Teva Pharmaceutical Industries Ltd
  • 10.10 Vectura Group Ltd
  • 10.11 Viatris Inc

List of Tables

  • Table 1 Global Inhalable Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Inhalable Drugs Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 3 Global Inhalable Drugs Market Outlook, By Long-acting Beta Antagonists (LABAs) (2021-2030) ($MN)
  • Table 4 Global Inhalable Drugs Market Outlook, By Inhaled Corticosteroids (2021-2030) ($MN)
  • Table 5 Global Inhalable Drugs Market Outlook, By Long-acting Muscarinic Antagonists (LAMAs) (2021-2030) ($MN)
  • Table 6 Global Inhalable Drugs Market Outlook, By Leukotriene Modifiers (2021-2030) ($MN)
  • Table 7 Global Inhalable Drugs Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 8 Global Inhalable Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 9 Global Inhalable Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 10 Global Inhalable Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 11 Global Inhalable Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 12 Global Inhalable Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 13 Global Inhalable Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 14 Global Inhalable Drugs Market Outlook, By Non-respiratory Diseases (2021-2030) ($MN)
  • Table 15 Global Inhalable Drugs Market Outlook, By Respiratory Diseases (2021-2030) ($MN)
  • Table 16 Global Inhalable Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 17 North America Inhalable Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 18 North America Inhalable Drugs Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 19 North America Inhalable Drugs Market Outlook, By Long-acting Beta Antagonists (LABAs) (2021-2030) ($MN)
  • Table 20 North America Inhalable Drugs Market Outlook, By Inhaled Corticosteroids (2021-2030) ($MN)
  • Table 21 North America Inhalable Drugs Market Outlook, By Long-acting Muscarinic Antagonists (LAMAs) (2021-2030) ($MN)
  • Table 22 North America Inhalable Drugs Market Outlook, By Leukotriene Modifiers (2021-2030) ($MN)
  • Table 23 North America Inhalable Drugs Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 24 North America Inhalable Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 25 North America Inhalable Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 26 North America Inhalable Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 27 North America Inhalable Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 28 North America Inhalable Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 29 North America Inhalable Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 30 North America Inhalable Drugs Market Outlook, By Non-respiratory Diseases (2021-2030) ($MN)
  • Table 31 North America Inhalable Drugs Market Outlook, By Respiratory Diseases (2021-2030) ($MN)
  • Table 32 North America Inhalable Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 33 Europe Inhalable Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 34 Europe Inhalable Drugs Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 35 Europe Inhalable Drugs Market Outlook, By Long-acting Beta Antagonists (LABAs) (2021-2030) ($MN)
  • Table 36 Europe Inhalable Drugs Market Outlook, By Inhaled Corticosteroids (2021-2030) ($MN)
  • Table 37 Europe Inhalable Drugs Market Outlook, By Long-acting Muscarinic Antagonists (LAMAs) (2021-2030) ($MN)
  • Table 38 Europe Inhalable Drugs Market Outlook, By Leukotriene Modifiers (2021-2030) ($MN)
  • Table 39 Europe Inhalable Drugs Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 40 Europe Inhalable Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 41 Europe Inhalable Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 42 Europe Inhalable Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 43 Europe Inhalable Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 44 Europe Inhalable Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 45 Europe Inhalable Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 46 Europe Inhalable Drugs Market Outlook, By Non-respiratory Diseases (2021-2030) ($MN)
  • Table 47 Europe Inhalable Drugs Market Outlook, By Respiratory Diseases (2021-2030) ($MN)
  • Table 48 Europe Inhalable Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 49 Asia Pacific Inhalable Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 50 Asia Pacific Inhalable Drugs Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 51 Asia Pacific Inhalable Drugs Market Outlook, By Long-acting Beta Antagonists (LABAs) (2021-2030) ($MN)
  • Table 52 Asia Pacific Inhalable Drugs Market Outlook, By Inhaled Corticosteroids (2021-2030) ($MN)
  • Table 53 Asia Pacific Inhalable Drugs Market Outlook, By Long-acting Muscarinic Antagonists (LAMAs) (2021-2030) ($MN)
  • Table 54 Asia Pacific Inhalable Drugs Market Outlook, By Leukotriene Modifiers (2021-2030) ($MN)
  • Table 55 Asia Pacific Inhalable Drugs Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 56 Asia Pacific Inhalable Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 57 Asia Pacific Inhalable Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 58 Asia Pacific Inhalable Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 59 Asia Pacific Inhalable Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 60 Asia Pacific Inhalable Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 61 Asia Pacific Inhalable Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 62 Asia Pacific Inhalable Drugs Market Outlook, By Non-respiratory Diseases (2021-2030) ($MN)
  • Table 63 Asia Pacific Inhalable Drugs Market Outlook, By Respiratory Diseases (2021-2030) ($MN)
  • Table 64 Asia Pacific Inhalable Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 65 South America Inhalable Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 66 South America Inhalable Drugs Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 67 South America Inhalable Drugs Market Outlook, By Long-acting Beta Antagonists (LABAs) (2021-2030) ($MN)
  • Table 68 South America Inhalable Drugs Market Outlook, By Inhaled Corticosteroids (2021-2030) ($MN)
  • Table 69 South America Inhalable Drugs Market Outlook, By Long-acting Muscarinic Antagonists (LAMAs) (2021-2030) ($MN)
  • Table 70 South America Inhalable Drugs Market Outlook, By Leukotriene Modifiers (2021-2030) ($MN)
  • Table 71 South America Inhalable Drugs Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 72 South America Inhalable Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 73 South America Inhalable Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 74 South America Inhalable Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 75 South America Inhalable Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 76 South America Inhalable Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 77 South America Inhalable Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 78 South America Inhalable Drugs Market Outlook, By Non-respiratory Diseases (2021-2030) ($MN)
  • Table 79 South America Inhalable Drugs Market Outlook, By Respiratory Diseases (2021-2030) ($MN)
  • Table 80 South America Inhalable Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 81 Middle East & Africa Inhalable Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 82 Middle East & Africa Inhalable Drugs Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 83 Middle East & Africa Inhalable Drugs Market Outlook, By Long-acting Beta Antagonists (LABAs) (2021-2030) ($MN)
  • Table 84 Middle East & Africa Inhalable Drugs Market Outlook, By Inhaled Corticosteroids (2021-2030) ($MN)
  • Table 85 Middle East & Africa Inhalable Drugs Market Outlook, By Long-acting Muscarinic Antagonists (LAMAs) (2021-2030) ($MN)
  • Table 86 Middle East & Africa Inhalable Drugs Market Outlook, By Leukotriene Modifiers (2021-2030) ($MN)
  • Table 87 Middle East & Africa Inhalable Drugs Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 88 Middle East & Africa Inhalable Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 89 Middle East & Africa Inhalable Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 90 Middle East & Africa Inhalable Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 91 Middle East & Africa Inhalable Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 92 Middle East & Africa Inhalable Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 93 Middle East & Africa Inhalable Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 94 Middle East & Africa Inhalable Drugs Market Outlook, By Non-respiratory Diseases (2021-2030) ($MN)
  • Table 95 Middle East & Africa Inhalable Drugs Market Outlook, By Respiratory Diseases (2021-2030) ($MN)
  • Table 96 Middle East & Africa Inhalable Drugs Market Outlook, By Other Applications (2021-2030) ($MN)